Posts Tagged ‘precision oncology’

New treatment may address imatinib-resistant tumors

Each year, 3,000 to 6,000 people are diagnosed with gastrointestinal stromal tumor (GIST)—the most common sarcoma of the gastrointestinal tract. Imatinib myeslate, or Gleevec®, has proved to be a highly effective therapy for many patients with GIST, although long-term survival is poor due to the development of imatinib-resistant GIST mutation types. Research recently published in Science Translational Medicine demonstrated promising results for a new treatment, BLU-285, which specifically targets two of the most common imatinib-resistant GIST mutations: KIT … Read More

Renowned scientist to lead precision oncology for the OHSU Knight Cancer Institute

Internationally renowned scientist Gordon B. Mills, M.D., Ph.D., is joining OHSU to lead precision oncology for the Knight Cancer Institute. One of the most highly cited medical scientists in the world, Mills will bring a breadth of research and leadership experience to OHSU. He was recruited from the MD Anderson Cancer Center in Houston, where he has been a clinical and research leader since 1994. At OHSU, Mills will integrate research across multiple areas, including early … Read More

Welcome to the Research News Blog

Welcome to the Research News Blog

OHSU Research News is your portal to information about all things research at OHSU. Find updates on events, discoveries, and important funding information.

Participation Guidelines

Remember: information you share here is public; it isn't medical advice. Need advice or treatment? Contact your healthcare provider directly. Read our Terms of Use and this disclaimer for details.

Categories

Archives